Friday, August 26, 2022
Athos Therapeutics, Inc. (referred to as "Athos") is an advanced-stage preclinical biotech company utilizing the power of Artificial Intelligence (AI) to develop innovative small molecule therapeutics for immune-mediated diseases and cancer. Today, Athos has announced a significant advancement in its internal omics AI platform through a collaboration with Caltech to incorporate proteomics analysis. This collaboration aims to revolutionize the field of Inflammatory Bowel Disease (IBD) by enhancing both the Athos platform and spectrometry-based proteomics.
Athos and Caltech will conduct spectrometry-based proteomics using cultured cells and biopsies obtained from archived and de-identified samples of IBD patients. The proteomics analyses will be closely correlated with detailed clinical information, including IBD subtypes, patient age, gender, disease location, prior treatments, and current status.
"We are thrilled to collaborate with Dr. Chou's esteemed proteomics research team at Caltech," expressed Dimitrios Iliopoulos, PhD, MBA, President & CEO of Athos. "By leveraging Caltech's state-of-the-art proteomics facilities, Athos will be able to gain comprehensive insights into the proteome of IBD patients, thus contributing to the identification of novel protein targets for drug development."
"All of us at Athos Therapeutics are extremely enthusiastic about integrating advanced, next-generation proteomics into our existing multi-omic AI platform," stated Allan Pantuck, MD, MS, FACS, Chairman, Founder & CMO of Athos. "At Dr. Chou's cutting-edge facility at Caltech, we will have the ability to accurately identify and quantify thousands of proteins from a single tissue sample. By incorporating this large-scale proteomic analysis with our existing genomic data, we will be able to extensively map disease networks, identify distinct patient subtypes, and discover new biomarkers and potential therapeutic targets."
This collaboration between Athos and Caltech holds great promise for advancing the understanding of IBD and paving the way for the development of effective treatments tailored to individual patients. By harnessing the power of AI and proteomics, Athos Therapeutics is poised to make significant strides in the fight against immune-mediated diseases and cancer.